WINTER PARK, Fla., Nov. 19 -- LaserSight Inc. has agreed with VISX Inc. to stay patent litigation filed by VISX on Nov. 15 and to continue negotiations on a US license agreement between the two companies. LaserSight has agreed to manufacture systems in the US but not to sell, offer to sell, ship or use the systems in the US until the parties enter into a license agreement or until the stay is otherwise lifted. LaserSight's activities outside the US are not restricted.
Earlier this week, LaserSight was informed of litigation filed by VISX, which alleged that LaserSight technology infringed one of VISX's US patents for opthalmic surgery equipment. LaserSight has stated that it does not believe these allegations to be true. The company was advised of the litigation one day after its announcement that its LaserScan LSX Excimer Laser System had received FDA pre-market approval for use in treating myopia of up to -6 diopters, with the ability to treat myopia of up to -10 diopters at the physician's discretion.